ArticleLaryngoscope investigative otolaryngology2025
Pre-Treatment Serum Prognostic Scores and Survival in Curatively Treated Laryngeal Cancer.
Article in Laryngoscope investigative otolaryngology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correction to "Pre-Treatment Serum Prognostic Scores and Survival in Curatively Treated Laryngeal Cancer".Laryngoscope investigative otolaryngology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Laryngeal squamous cell cancer (LSCC) is a common head and neck cancer subtype, primarily linked to smoking and alcohol use. Despite declining incidence, survival outcomes have not improved. Prognostic scores, derived from blood-based markers like neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and systemic immune-inflammation index (SIII), are increasingly recognized for their potential to predict survival outcomes and guide patient management. Methods: A retrospective analysis of 473 LSCC patients diagnosed in the West of Scotland (2014-2020) assessed the association of prognostic scores with overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS). Patients were categorized into high- and low-risk groups based on combined scores. Results: Low LMR and high-risk scores were significantly associated with worse OS, CSS, and RFS. Nodal status and disease stage remained strong predictors. Combining clinicopathological variables with prognostic scores improved survival prediction. Conclusion: Prognostic scores are valuable tools for survival prediction in LSCC and, when combined with clinicopathological factors, may guide patient management. Further validation is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.